SNM SCANcast: New PET synthesizer readies for market entry
A new, compact synthesizer of PET radiotracers -- about a third the size of systems currently available -- is poised to enter the U.S. market later this year. Hear an interview with its inventor, Maxim Kiselev, Ph.D., vice president of R&D for IBA Molecular.
A new, compact synthesizer of PET radiotracers - about a third the size of systems currently available - is poised to enter the U.S. market later this year. Synthera, developed by IBA (Ion Beam Applications) Molecular and priced at about $96,000, was unveiled at the Society of Nuclear Medicine meeting June 3 to 7 in San Diego. Its core component, the ejectable Integrated Fluidic Processor, makes it a true multirun system capable of producing various radiotracers, including FDG, according to its inventor, Maxim Kiselev, Ph.D., vice president of R&D for IBA Molecular. (hear a two-minute interview with Kiselev from the SNM exhibit floor)
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
